62P Ecto-CRT induction of NKp46 surface expression increases osimertinib-resistant lung cancer’s sensitivity to NK cells

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have dramatically changed lung cancer treatment modalities and improved EGFR-mutated non-small cell lung cancer (NSCLC) patients’ prognosis over the past two decades. Third-generation EGFR-TKI, Osimertinib, has resulted in impressive success both in the first-line treatment setting and as a salvage therapy in the presence of the T790M secondary mutation. However, most patients inevitably develop resistance, with therapeutic options limited to platinum-based chemotherapy.